Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Plamotamab by Xencor for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Plamotamab is under clinical development by Xencor and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
Plamotamab by Xencor for Non-Hodgkin Lymphoma: Likelihood of Approval
Plamotamab is under clinical development by Xencor and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Xencor's Plamotamab?
Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory...